Mr. Welch has served as a member of the Ultragenyx Board since April 2015. Mr. Welch is currently Executive Chairman at Levo Therapeutics, Inc., and Executive Chairman of Incarda Therapeutics, Inc., positions he has held since August 2018 and March 2019, respectively. Prior to these roles he was an Executive Partner at Sofinnova Ventures from January 2015 through January 2018. From September 2003 until its acquisition by Roche Holdings in September 2014, Mr. Welch served as Chief Executive Officer and President of InterMune, Inc., a biotechnology company. Mr. Welch also served as Chairman of InterMune from May 2008 to September 2014. From August 2002 to January 2003, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc. From October 2000 to June 2002, Mr. Welch served as President of the pharmaceutical division of Elan Corporation, PLC. Mr. Welch also currently serves on the Boards of Directors of Seattle Genetics, Inc., Intercept Pharmaceuticals, Inc. and Nuvation Bio Inc. He holds a B.A. from the University of Miami and an M.B.A. from the University of North Carolina.